Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Am J Psychiatry ; 158(12): 1989-92, 2001 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-11729014

RESUMEN

OBJECTIVE: Serotonin selective reuptake inhibitors (SSRIs) are now considered the first-line pharmacotherapy for panic disorder. The preferential use and the presumption of greater tolerability of SSRIs relative to older agents, such as tricyclic antidepressants, occurred without direct comparisons between the two classes of medication. In this study the authors used an effect-size analysis to provide an initial comparison. METHOD: The authors conducted an effect-size analysis of 12 placebo-controlled, efficacy trials of SSRIs for panic disorder and compared these results to findings obtained in a recent meta-analysis of non-SSRI treatments for panic disorder. RESULTS: The mean effect size for acute treatment outcome for SSRIs relative to placebo was 0.55, not significantly different from that for antidepressants in general (0.55) and for imipramine in particular (0.48). More recent studies of SSRIs, and studies using larger samples, were associated with lower effect sizes. No significant differences were found in dropout rates between those taking SSRIs and those taking older agents during acute treatment. CONCLUSIONS: An effect-size analysis of controlled studies of treatments for panic disorder revealed no significant differences between SSRIs and older antidepressants in terms of efficacy or tolerability in short-term trials. An inverse relationship was evident between sample size and effect size for SSRIs. Early studies of small samples may have led to initial overestimations of the efficacy of SSRIs for panic disorder.


Asunto(s)
Trastorno de Pánico/tratamiento farmacológico , Inhibidores Selectivos de la Recaptación de Serotonina/uso terapéutico , Humanos , Trastorno de Pánico/diagnóstico , Trastorno de Pánico/psicología , Ensayos Clínicos Controlados Aleatorios como Asunto , Inhibidores Selectivos de la Recaptación de Serotonina/efectos adversos , Resultado del Tratamiento
2.
Ann Clin Psychiatry ; 10(2): 75-80, 1998 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-9669539

RESUMEN

Dizziness is a common and costly condition that causes significant distress and impairment yet often confounds appropriate diagnosis and treatment. Among patients presenting for evaluation and treatment of dizziness, rates of panic disorder are elevated to 5 to 15 times the general population rates. In addition, the limited studies to date of dizziness in patients with panic disorder suggest that panic patients frequently experience significant dizziness and often demonstrate evidence of vestibular dysfunction. In this paper we review studies investigating the relationship between panic disorder and vestibular dysfunction. Currently, there are three main explanatory models for the association between panic disorder and vestibular dysfunction: the psychosomatic model, the somatopsychic model, and the network alarm theory. Systematic investigations of the treatment of patients with vestibular symptoms and panic disorder are lacking, though prevalence, associated costs, and disability suggest that they are needed. Serotonin selective reuptake inhibitors are good candidates for future treatment studies.


Asunto(s)
Ansiedad/fisiopatología , Mareo/fisiopatología , Trastorno de Pánico/fisiopatología , Enfermedades Vestibulares/complicaciones , Agorafobia/complicaciones , Agorafobia/fisiopatología , Ansiolíticos/uso terapéutico , Antidepresivos/uso terapéutico , Benzodiazepinas , Mareo/complicaciones , Mareo/psicología , Humanos , Modelos Psicológicos , Trastorno de Pánico/complicaciones , Trastorno de Pánico/tratamiento farmacológico , Trastornos Psicofisiológicos/clasificación , Trastornos Somatomorfos/clasificación , Enfermedades Vestibulares/fisiopatología , Enfermedades Vestibulares/psicología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...